Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25333060 | 1.00 | SPHK1 (0.56) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL13258710 | 0.83 | LTA4H (0.62) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL26266218 | 0.83 | SPHK1 (0.68) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL14850430 | 0.83 | SPHK1 (0.57) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL24395095 | 0.83 | SPHK1 (0.57) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL17661962 | 0.82 | LTA4H (0.56) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL17637516 | 0.82 | LTA4H (0.56) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL25332170 | 0.81 | HRH3 (0.42) | SPHK1LTA4HHRH3 | |
| SCHEMBL25332163 | 0.81 | HRH3 (0.42) | SPHK1LTA4HHRH3 | |
| SCHEMBL19750625 | 0.81 | SPHK1 (0.64) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4469090-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | Genentech Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | SPHK1 4350/4885SPHK2 4288/4885S1PR1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.